A real world multi centre study on efficacy and safety of natalizumab in indian patients with multiple sclerosis

T. Mathew,V. Kamath,S. K. John,M. Netravathi, B. Rajesh Iyer, S. Raghavendra, R. SureshKumar, N. R. Ichaporia, M. Neeharika, P. Singh,S. Gupta,R. K. Annadure,A. Rohatgi,S. Sruthi Nair,R. Umashankar, V. Arul Selvan,Y. Muralidhar Reddy,U. A. Murgod, Y. Sirisha, R. ShivaKumar,G. Sarma,R. Nadig,B. Anand,N. Surya,P. Satishchandra, B. S. Singhal,G. Parry

MULTIPLE SCLEROSIS JOURNAL（2022）

引用 0|浏览3

暂无评分

摘要

•The largest ambispective study from a developing country on natalizumab and multiple sclerosis.•Natalizumab was found to be highly effective in Indian patients with MS.•Patients with RRMS and SPMS improved in relapse rate while EDSS improvement was observed only in the RRMS cohort.•The risk-benefit ratio appears highly favorable with no reports of PML.

查看译文

关键词

Multiple sclerosis,Natalizumab,Relapse rate,EDSS score,Progressive multifocal leukoencephalopathy,JC virus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要